

REMARKS

Upon entry of this response, claims 1-20 are pending. Claim 19-20 have been added. No claims have been amended or canceled. No new matter has been added by way of this response.

Election/Restrictions Required

In the Official Action of April 16, 2007, the Office required an election of one of the following inventions under 35 U.S.C. § 372:

Group I: Claims 1-15, drawn to products and methods of using the compound of formula (I) where **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is substituted phenyl; as depicted in Claim 1, pages 3-5 and Example 1 of the specification.

Group II: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is substituted pyrrolidine; as depicted in Claim 1, pages 3-5 and Example 3 of the Specification.

Group III: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is biphenyl; as depicted in Claim 1, pages 3-5 and Example 5 of the Specification.

Group IV: Claims 1-15, drawn to products and methods of using the compound of formula (I) wherein **X** is NH; **Y** is -NH-CO; **Ar1** and **Ar2** are phenyl; **A** is -C(=NH)NH₂, **G** is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and **R3** is phenyl-morpholine; as depicted in Claim 1, pages 3-5 and Example 8 of the Specification.

Group V: Claims 16-18, drawn to methods of using the compound of formula (I) where in the disorder is arterial restenois.

In response to the Office's invention restriction requirement, Applicants *provisionally* elect, with traverse, to prosecute the invention of Group I, encompassing claims 1-15, drawn to products and methods of using the compound of formula (I) where X is NH; Y is -NH-CO; Ar1

and Ar2 are phenyl; A is -C(=NH)NH2, G is a glycosyl group, which is 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy; and R3 is substituted phenyl. An example of an embodiment of such invention group is the compound of Example 45, which is 2-(3-Carbamimidoyl-phenylamino)-N-[4-(morpholin-4-carbonyl)-phenyl]-2-[2-(- 3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-acetamide). The provision of such example herein is intended only to aid the Office and is not to be understood as any further election over Group I, for example a species election.

Applicants hereby reserve the right to pursue non-elected invention groups (for example, Group II (claims 1-15), Group III (claims 1-15), Group IV (claims 1-15), Group V (Claims 16-18), or any other invention group) in this application where rejoinder is appropriate or in a subsequently filed application claiming the benefit of the present application. It is Applicants' understanding that the substituted phenyl of R3, as described by the Office in invention Group I, is not directed to a particular substitution position or moiety.

Applicants herein present new claims 19-20. Claim 19 corresponds to the independent claim of issued European Patent EP1470143 (in German), which is the priority document for PCT/EP2003/001011 (published as WO2003/064440), from which the present application was filed.

In traversing the restriction requirement, Applicants respectfully assert that examination and issuance of corresponding claims in EP1470143 provides *prima facie* evidence that at least claims 19-20 of the present application are not drawn to more than one inventive concept and that the special technical features of claims 19-20 provide a technical relationship sufficient to establish unity of invention. Applicants respectfully request the Office to classify at least claims 19-20 in a single invention Group and provide substantive examination thereof.

CONCLUSION

Applicants believe that the claims as presented represent allowable subject matter. If the Office desires, Applicants welcome a telephone interview to expedite prosecution. As always, the Office is free to call the undersigned at the number below. Applicants believe there is a \$225.00 fee for a two month extension due at this time. The Commissioner is hereby authorized to deduct any deficiency or credit any overpayment with respect to this response to Deposit Account No. 19-3140.

Respectfully submitted,

SONNENSCHN NATH & ROSENTHAL LLP

By: /David R. Metzger/
David R. Metzger
Reg. No. 32,919
Telephone No. 312.876.2578

ATTORNEYS FOR APPLICANT